The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent.
The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent. After reviewing more than 6000 clinical charts of patients who received vancomycin therapy and whose serum vancomycin level was monitored between January 2010 and December 2013, we identified 212 patients who also had diagnosed as severe acute pancreatitis (SAP group), and 98 patients who also had diagnosed as pneumonia (pneumonia group) at that time. The fluorescence polarization immunoassay method was used to measure vancomycin serum trough concentrations in these patients 30 min before the next administration. Using these measurements, we calculated the pharmacokinetic parameters using the Bayesian estimator.
Study Type
OBSERVATIONAL
Enrollment
200
Ruijin Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGvancomycin serum trough concentrations in these patients just prior to the next vancomycin serum trough concentrations was measured
vancomycin serum trough concentrations was measured in patients just prior to the next dose at steady-state conditions (approximately after the fourth dose).
Time frame: patients will be followed for the duration of hospital stay, an expected average of 5 weeks
the pharmacokinetic parameters was calculated using the Bayesian estimator.
Time frame: patients will be followed for the duration of hospital stay, an expected average of 5 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.